- Home
- CRBP vs ILLR Comparison
CRBP vs ILLR Comparison
Compare CRBP & ILLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- ILLR
- Stock Information
- Founded
- CRBP 2009
- ILLR 2015
- Country
- CRBP United States
- ILLR United States
- Employees
- CRBP N/A
- ILLR N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- ILLR Investment Managers
- Sector
- CRBP Health Care
- ILLR Finance
- Exchange
- CRBP Nasdaq
- ILLR Nasdaq
- Market Cap
- CRBP 114.8M
- ILLR 122.5M
- IPO Year
- CRBP N/A
- ILLR N/A
- Fundamental
- Price
- CRBP $16.22
- ILLR $0.83
- Analyst Decision
- CRBP Strong Buy
- ILLR
- Analyst Count
- CRBP 8
- ILLR 0
- Target Price
- CRBP $50.57
- ILLR N/A
- AVG Volume (30 Days)
- CRBP 221.8K
- ILLR 1.7M
- Earning Date
- CRBP 11-06-2025
- ILLR 11-13-2025
- Dividend Yield
- CRBP N/A
- ILLR N/A
- EPS Growth
- CRBP N/A
- ILLR N/A
- EPS
- CRBP N/A
- ILLR N/A
- Revenue
- CRBP N/A
- ILLR $45,244,000.00
- Revenue This Year
- CRBP N/A
- ILLR N/A
- Revenue Next Year
- CRBP $220.00
- ILLR N/A
- P/E Ratio
- CRBP N/A
- ILLR N/A
- Revenue Growth
- CRBP N/A
- ILLR N/A
- 52 Week Low
- CRBP $4.64
- ILLR $0.40
- 52 Week High
- CRBP $20.77
- ILLR $5.98
- Technical
- Relative Strength Index (RSI)
- CRBP 76.29
- ILLR 48.53
- Support Level
- CRBP $15.00
- ILLR $0.86
- Resistance Level
- CRBP $16.97
- ILLR $1.00
- Average True Range (ATR)
- CRBP 1.01
- ILLR 0.10
- MACD
- CRBP 0.28
- ILLR -0.03
- Stochastic Oscillator
- CRBP 88.62
- ILLR 30.07
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.